Intron Biotechnology, Inc.

Sooyoun Jun

Sanghyeon Kang

Seongjun Yoon

Jeesoo Son

Yunjaie Choi

Hyoungrok Paik

Seyung Lee

Seong Jun Yoon

Jinseok Yu

Yoonsik Shin

Se Yung Lee

Hyunyoung Lee

Gimo Jung

Se Jung Lee

The present invention relates to a PCR primer facilitating hot-start PCR by suppressing non-specific amplification at room temperature and at the same time capable of reducing significantly non-specific amplification by dominating the amplification of the PCR product rather than the amplification of the original template from the third PCR cycle, more precisely a PCR primer prepared by additionally inserting the reverse-complementary sequence to a certain region starting from the 5'-start site of the 5&#x2032;-terminus of the original primer which is composed of priming sequence to anneal to a PCR template into the 5&#x2032;-terminus of the original primer and a PCR method using the same. The primer of the present invention has a original primer sequence composed of priming sequence to anneal to a PCR template and an additional reverse-complementary sequence, which inserted into the 5&#x2032;-terminus of the original primer, to a certain region starting from the 5&#x2032;-start site of the 5&#x2032;-terminus of the original primer sequence, suggesting that a template-specific sequence and its reverse-complementary sequence are included in the same primer. The present invention can improve PCR specificity by reducing non-specific amplification.

PCR primer capable of reducing non-specific amplification and PCR method using the PCR primer

The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroyingonce being infected in, as an active ingredient, and a method for prevention and treatment ofinfection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity toand has the genome represented by SEQ. ID. NO: 1.

[object Object]

The present invention relates to a composition comprising EK99P-1, a bacteriophage isolated from nature and capable of infectingtype K99 so as to kill the same, as an active ingredient, and a method for preventing and treatingtype K99 infections using the said composition. According to the present invention, the bacteriophage EK99P-1, an active ingredient of the composition, has a killing activity againsttype K99 and has the genome represented by SEQ. ID. NO: 1.

The present invention relates to a method for the preparation of a labeling agent derived from one type of tRNA prepared by in vitro transcription, which is usable for non-radioactive selective labeling of target proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of target proteins produced by in vitro translation using the labeling agent without labeling pre-existing proteins in the reaction mixture.

Method for selective labeling of protein produced by in vitro translation by using a marker from tRNA prepared by using in vitro transcription

The present invention relates to compositions for removing a biofilm formed by, comprising a, such as Myoviridae family T4-like phage genus(Accession No: KCTC 11153BP, SAP-1) or Podoviridae family &#x3c6;29-like virus genus(Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused bycapable of forming biofilm.

The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific towhich is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.

The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.

Composition for the treatment of ballast water containing bacteriophage as an effective component and biological method with the same for removing bacteria present in ballast water

The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.

Lysin protein having broad antibacterial activity specific to bacteria

The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific towhich is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.

Growing community of inventors

Seoul, South Korea

Sooyoun Jun